The European Medicines Agency’s Committee on Herbal Medicinal Products (HMPC) has presented its Work Plan for 2026, signaling its intent to influence the landscape of herbal medicine regulation across the EU. This document directly affects herbal medicine producers, EU regulatory bodies, healthcare professionals, and consumers seeking herbal treatments, sparking a spectrum of responses from promoting safety to concerns over regulatory burdens.
Published on January 30, 2026, by the EMA’s HMPC, this document outlines the strategic activities planned for the coming year. The HMPC, a specialised committee within the EMA, focuses exclusively on herbal medicinal products, ensuring harmonised standards across member states.
The Work Plan is an orientative policy document rather than binding legislation. It details specific initiatives and evaluation priorities but does not impose mandatory rules or numerical targets. Instead, it sets a framework for advancing regulatory clarity, fostering scientific assessment, and enhancing the availability and safety monitoring of herbal medicines within the EU.
The plan prioritises strengthening regulatory oversight by promoting clearer definitions and evaluation criteria for herbal products. It leans towards increasing EMA’s influence in harmonising standards, potentially reducing member states’ individual flexibility on herbal product assessment. This reflects a trade-off between deeper EU integration in herbal regulation and national sovereignty concerns. The plan also suggests heightened scrutiny and transparency around safety data, aiming to protect consumers without drastically increasing burdens on business competitiveness.
herbal medicine producers may face moderate compliance costs due to enhanced scientific requirements but benefit from clearer guidelines facilitating market access. EU regulatory bodies strengthen their supervisory role, gaining refined tools for evaluation. Consumers stand to gain from improved safety and product consistency, while healthcare providers receive updated assessments aiding clinical decisions. Conversely, some national authorities might view increased EU coordination as a reduction in their traditional regulatory autonomy.
This Work Plan marks the start of the 2026 regulatory agenda for herbal medicines. It sets the scene for subsequent detailed guidance and evaluation activities by EMA and invites feedback from stakeholders. The European Commission and national regulatory agencies are expected to engage as the plan’s priorities are operationalised, shaping the future trajectory of herbal medicinal product oversight within the EU.
← Atlas › News